<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250809066791N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-11-04</date_registration>
      <primary_sponsor>Qazvin University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of hypobaric unilateral spinal anesthesia versus general anesthesia on heart rate, blood pressure change and mortality in hip fracture surgery</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of hypobaric unilateral spinal anesthesia versus general anesthesia on heart rate, blood pressure change and mortality in hip fracture surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/85474</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>3</phase>
      <hc_freetext>Hip fracture surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Unilateral Spinal Anesthesia with Ropivacaine and Sufentanil: In this group, patients undergo Unilateral Spinal Anesthesia (ULSA). After injecting 500 cc of normal saline, the patient is placed in a sitting position. The hypobaric anesthetic solution is prepared with the following ingredients: 0.5% Ropivacaine, 2 ml (10 mg) of Sufentanil, 1 ml (5 μg) of distilled water, 1 ml. A total of 4 cc of the prepared solution is injected into the subarachnoid space L4–L5 (or a higher or lower space) with a 23 G needle. After injection, the patient is placed in a lateral position on the non-involved side (fracture area upwards) for 5 minutes to limit the spread of the drug to that side. In case of mild pain during the procedure (NRS &lt;4), an opioid infusion is used. If the patient's pain is not controlled, general anesthesia is performed and the patient is excluded from the study. Monitoring of mean arterial blood pressure (MAP) and heart rate is performed every 3 minutes, as in the control group, and in case of hypotension, treatment with ephedrine and, if necessary, norepinephrine is performed. Intervention 2: Control group: General anesthesia with isoflurane and standard induction drugs: In this group, patients are put under general anesthesia. After injecting 500 cc of normal saline and premedication with midazolam at a dose of 0.02 mg/kg, sufentanil at a dose of 0.2 μg/kg, propofol at a dose of 1 mg/kg, and atracurium at a dose of 0.5 mg/kg, anesthesia is used to induce anesthesia. After ensuring proper airway conditions and performing endotracheal intubation, the patient's anesthesia is maintained with isoflurane and oxygen/medical air based on the patient's hemodynamic status. During the procedure, mean arterial blood pressure (MAP) and heart rate are monitored every 3 minutes. In case of hypotension, a bolus of ephedrine 5 to 10 mg is first injected and repeated if necessary up to a maximum of 20 mg. If hypotension persists, norepinephrine infusion is initiated at a dose of 5–10 μg/min. At the end of the procedure, the patient is monitored and data are recorded for hemodynamic parameters during recovery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Obtaining satisfaction from participants</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Tarokh Rajabinezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bahonar Blvd</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>34197-58911</zip>
        <telephone>+98 28 3333 6001</telephone>
        <email>Tarokhrajabinezhad@gmail.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Tarokh Rajabinezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bahonar Blvd</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>34197-58911</zip>
        <telephone>+98 28 3333 6001</telephone>
        <email>tarokhrajabinezhad@gmail.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>People over 60 years of age who visit Shahid Rajaee Hospital in Qazvin and undergo orthopedic surgery due to a hip fracture</inclusion_criteria>
      <agemin>60 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergy to ropivacaine
Multiple trauma</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S72.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fracture of head and neck of femur</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Unilateral Spinal Anesthesia with Ropivacaine and Sufentanil: In this group, patients undergo Unilateral Spinal Anesthesia (ULSA). After injecting 500 cc of normal saline, the patient is placed in a sitting position. The hypobaric anesthetic solution is prepared with the following ingredients: 0.5% Ropivacaine, 2 ml (10 mg) of Sufentanil, 1 ml (5 μg) of distilled water, 1 ml. A total of 4 cc of the prepared solution is injected into the subarachnoid space L4–L5 (or a higher or lower space) with a 23 G needle. After injection, the patient is placed in a lateral position on the non-involved side (fracture area upwards) for 5 minutes to limit the spread of the drug to that side. In case of mild pain during the procedure (NRS &lt;4), an opioid infusion is used. If the patient's pain is not controlled, general anesthesia is performed and the patient is excluded from the study. Monitoring of mean arterial blood pressure (MAP) and heart rate is performed every 3 minutes, as in the control group, and in case of hypotension, treatment with ephedrine and, if necessary, norepinephrine is performed.</i_keyword>
      <i_keyword>Control group: General anesthesia with isoflurane and standard induction drugs: In this group, patients are put under general anesthesia. After injecting 500 cc of normal saline and premedication with midazolam at a dose of 0.02 mg/kg, sufentanil at a dose of 0.2 μg/kg, propofol at a dose of 1 mg/kg, and atracurium at a dose of 0.5 mg/kg, anesthesia is used to induce anesthesia. After ensuring proper airway conditions and performing endotracheal intubation, the patient's anesthesia is maintained with isoflurane and oxygen/medical air based on the patient's hemodynamic status. During the procedure, mean arterial blood pressure (MAP) and heart rate are monitored every 3 minutes. In case of hypotension, a bolus of ephedrine 5 to 10 mg is first injected and repeated if necessary up to a maximum of 20 mg. If hypotension persists, norepinephrine infusion is initiated at a dose of 5–10 μg/min. At the end of the procedure, the patient is monitored and data are recorded for hemodynamic parameters during recovery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severe hypotension during surgery. Timepoint: From the start of anesthesia to the end of the surgery. Method of measurement: Non-invasive blood pressure measurement with standard monitoring every three minutes.</prim_outcome>
      <prim_outcome>Intraoperative norepinephrine intake. Timepoint: From the start of anesthesia or numbing to the end of the surgery. Method of measurement: Total dose recorded on the anesthesia sheet.</prim_outcome>
      <prim_outcome>Amount of ephedrine taken during surgery. Timepoint: From the start of anesthesia or numbing to the end of the surgery. Method of measurement: Total dose recorded on the anesthesia sheet.</prim_outcome>
      <prim_outcome>Seven-day postoperative mortality. Timepoint: From the end of surgery to seven days later. Method of measurement: Clinical follow-up and hospital record review.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Qazvin University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-11-02</approval_date>
        <contact_name>Ethics committee of Qazvin University of Medical Sciences</contact_name>
        <contact_address>Research and Technology deputy ,Mavaddat Alley,Shahid Beheshti Blvd Qazvin Qazvin Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
